His case was considered a milestone for #MeToo, in which women accused hundreds in entertainment, media, politics and other fields of sexual misconduct
The Indian drug regulator's subject expert committee has recommended emergency use approval for Zydus Cadila's three-dose Covid-19 vaccine, CNBC-TV18 reported on Friday, citing sources.
The committee added that Zydus needs to submit additional data for the 2-dose regimen of its vaccine, CNBC-TV18 said in a tweet.
The generic drugmaker, listed as Cadila Healthcare Ltd, applied for the authorisation of the vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6 per cent in a late-stage trial of more than 28,000 volunteers nationwide.
If approved, Zydus Cadila's vaccine will be the second home-grown shot to get emergency authorisation in India after Bharat Biotech's Covaxin.
Zydus Cadila and India's drug regulator did not immediately respond to a Reuters request for comment.
His case was considered a milestone for #MeToo, in which women accused hundreds in entertainment, media, politics and other fields of sexual misconduct
Well-known communication expert Maha Abouelenein on what it takes to thrive in the age of social media
From cultural events, and culinary delights to outdoor adventures, here's a line-up of thrilling activities to make your weekend exciting
'The rom-com garnered $219 million worldwide after its premiere in December
The guitar will be auctioned on May 29 at the Hard Rock Cafe in New York
Fitness enthusiast Sarah Lindsay shares insights on what it takes to embark on a fitness journey and sustain it amidst a busy lifestyle
Such platforms help women to re-enter the workforce by equipping them with new-age skills, upskilling, polishing their interviewing skills and revamping their resumes
Official autism-friendly in-flight certification is in the works, possibly used by other airlines